scholarly journals Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Xin-Wei He ◽  
Wei-Ling Li ◽  
Cai Li ◽  
Peng Liu ◽  
Yu-Guang Shen ◽  
...  
Keyword(s):  
Serum Levels ◽  
Large Artery ◽  
Galectin 3

scholarly journals Dynamics of Galectin-3 serum levels after percutaneous occlusion of the left atrial appendage: a new surrogate parameter for successful LAA closure?

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
F Haertel ◽  
S Ijuin ◽  
P Lustermann ◽  
K Gruen ◽  
A Hamadanchi ◽  
...  
Keyword(s):  
Functional Outcome ◽  
Left Atrial ◽  
Left Atrial Appendage ◽  
Tissue Remodeling ◽  
Serum Levels ◽  
Atrial Appendage ◽  
Left Ventricular Ejection ◽  
Bleeding Complications ◽  
Tenascin C ◽  
Galectin 3

Abstract Introduction Left atrial cardiac tissue remodeling following left atrial appendage closure (LAAC) is a scientifically neglected phenomenon until now but might have impact on functional outcome of patients suffering from atrial fibrillation (AF). Thus, our study is focused on quantification of key biomarkers reflecting fibrosis development as a major component within cardiovascular tissue remodeling. Methods Patients (CHA2DS2VASC score ≥1, HASBLED score ≥3) with bleeding complications under anticoagulation therapy and therefore eligible for LAAC were included in the present study. Serum levels of biomarkers of cardiac fibrosis and remodeling (Galectin-3, ST2/IL-2, ST2/IL-1, B domain containing Tenascin-C (B+ Tn-C), C domain containing Tenascin- C (C+ Tn-C)) were determined before device implantation (baseline), 45 days (45d) and 6 months (6M) after LAAC using commercially available ELISAs. To quantify functional outcome, all patients performed a 6-minutes walk test (6- MWT). Transesophageal echocardiography (TEE) was carried out to assess success of the LAAC procedure regarding peri-device leakage (PDL). Results We included 33 patients (age: 73.5±6.7 years; 21 men (64%) and 12 women (36%); BMI: 29.1±5.1 kg/m2; CHA2DS2VASC score: 4.2±1.2; left ventricular ejection fraction: 61.1±9.3%; mean occluder size: 25.9±3.9 mm; type of AF: 46% paroxysmal (15 patients), 55% permanent (18 patients)). Complete LAAC (without any residual low) was achieved in 60% (19 patients) after 45 days and in 87% (29 patients) after 6 months. At baseline, Galectin-3 levels did not show a relevant difference regarding the type of AF (paroxysmal AF: 14.7±5.4 ng/ml vs. permanent AF: 13.1±6.3 ng/ml; p=0.45). We observed a significant increase of serum levels of Galectin-3 [ng/ml] after 45 days vs. baseline (baseline: 13.3±5.8 vs. 45d: 18.3±10.6; p=0.005) with a return to baseline levels after 6 months (baseline: 13.3±5.8 vs. 6M: 12.5±5.4; p=0.28). Compared to patients with successful LAAC, patients with PDL had a trend towards higher levels of Galectin-3 after 6 months (11.3±5.5 ng/ml vs. 16.1±4.1 ng/ml, p=0.09). Measurements of other fibrosis markers were statistically not significantly different. The walking distance measured by the 6-MWT increased significantly from 298.5±89.5 meters at baseline to 335.5±95.1 meters (p=0.04) after 45d and remained significantly elevated after 6M (346.7±122.7 meters; p=0.02). Conclusion The implantation of an LAA occluder device is accompanied by significantly increased circulating levels of the fibrosis biomarker Galectin-3 after 45 days in patients with AF. The regression in serum levels after 6 months probably reflects a successful fibrotic remodeling in the left atrial appendage over time and might be used as surrogate parameter for LAAC success. Increased and stable exercise tolerance after 45 days can be observed. Funding Acknowledgement Type of funding source: None

scholarly journals Galectin-3—A New Player of Kidney Damage or an Innocent Bystander in Children with a Single Kidney?

2021 ◽  
Vol 10 (9) ◽  
pp. 2012
Author(s):  
Eryk Latoch ◽  
Katarzyna Konończuk ◽  
Anna Jander ◽  
Elżbieta Trembecka-Dubel ◽  
Anna Wasilewska ◽  
...  
Keyword(s):  
Reference Group ◽  
Kidney Injury ◽  
Serum Levels ◽  
Kidney Damage ◽  
Serum Cystatin C ◽  
Galectin 3 ◽  
Potential Applicability ◽  
Area Under Roc Curve ◽  
Early Biomarker ◽  
Auc Value

The aim of this study was to evaluate the galectin-3 (Gal-3) level in children with a congenital solitary functioning kidney (cSFK) and determine its association with common renal function parameters. The study consisted of 68 children (49 males) with cSFK. We demonstrated that children with cSFK had a lower level of galectin-3 than that of healthy subjects (p < 0.001). No significant differences in serum cystatin C (Cys C) levels between the cSFK children and the reference group were found. The subjects with cSFK and reduced estimated glomerular filtration rate (eGFR) had significantly higher levels of Gal-3 and Cys C compared to those with normal eGFR (p < 0.05). Children with eGFR <60 mL/min/1.73 m2 showed significant statistical differences between the values of area under ROC curve (AUC) for Gal-3 (AUC 0.91) and Cys C (AUC 0.96) compared to that for creatinine level (AUC 0.76). Similar analyses carried out among cSFK children with eGFR <90 mL/min/1.73 m2 revealed an AUC value of 0.69 for Gal-3, 0.74 for Cys C, and 0.64 for creatinine; however, no significant superiority was shown for any of them. The receiver operating characteristic (ROC) analyses for identifying the SFK children among all participants based on the serum levels of Gal-3 and Cys C did not show any diagnostic profile (AUCs for Gal-3 and Cys C were 0.22 and 0.59, respectively). A positive correlation between the Gal-3 and Cys C concentrations was found (r = 0.39, p = 0.001). We demonstrated for the first time that Gal-3 might play an important role in the subtle kidney damage in children with cSFK. However, further prospective studies are required to confirm the potential applicability of Gal-3 as an early biomarker for kidney injury and possible progression to CKD.

Evaluation of the serum levels of galectin-3 in patients with oral lichen planus disease

Oral Diseases ◽  
2019 ◽  
Vol 25 (2) ◽  
pp. 466-470 ◽  
Author(s):  
Janan Ghapanchi ◽  
Azadeh Andisheh-Tadbir ◽  
Pooriya Torkaman ◽  
Mahyar Malekzadeh ◽  
Maryam Mardani
Keyword(s):  
Lichen Planus ◽  
Oral Lichen Planus ◽  
Serum Levels ◽  
Galectin 3 ◽  
Oral Lichen

scholarly journals LGALS3 +191A and +292C polymorphisms are associated with a reduction in serum gal-3 levels, but not with the clinical events of individuals with sickle cell anemia

2020 ◽  
Vol 9 (9) ◽  
pp. e442997314
Author(s):  
Kleyton Palmeira do Ó ◽  
Taciana Furtado de Mendonça-Belmont ◽  
Isabela Cristina Cordeiro Farias ◽  
Andreia Soares da Silva ◽  
Ana Karla da Silva Freire ◽  
...  
Keyword(s):  
Single Nucleotide Polymorphisms ◽  
Sickle Cell ◽  
Sickle Cell Anemia ◽  
Serum Levels ◽  
Nucleotide Polymorphisms ◽  
Single Nucleotide ◽  
Clinical Events ◽  
Genotype Frequencies ◽  
Galectin 3 ◽  
Taqman Pcr

Objective: This study aimed to evaluate whether the single nucleotide polymorphisms (SNPs) +191 C>A (rs4644) and +292 A>C (rs4652) of the LGALS3 gene and the serum levels of galectin-3 (gal-3) are associated with clinical events in patients with sickle cell anemia (SCA). Methods: SNP +191 and +292 of the LGALS3 gene were detected by the TaqMan PCR system in real time. Gal-3 levels were measured in serum by ELISA. The study included 322 patients, mean age 36 (21-84). Results: AA and CA genotypes of the +191 region were related to lower levels of gal-3 when compared to CC genotype (p=0.0296). Lower level of gal-3 was also associated with the +191/+292 (AA/CC; CA/CC) diplotypes (p=0.0137) compared to the diplotypes (CC/AA; CC/CC; CC/AC; CA/AC). There was no association between serum levels of galectin-3 and genotype frequencies of the LGALS3 +191 and +292 polymorphisms with clinical events in SCA. Conclusion: The polymorphisms +191 and +292 of the LGALS3 are associated to decrease in serum levels of gal-3. However, no association of polymorphisms and levels of gal-3 with clinical events was observed in patients SCA.

Angiopoietin-like protein 4 serum levels and gene polymorphisms are associated with large artery atherosclerotic stroke

2016 ◽  
Vol 362 ◽  
pp. 333-338 ◽  
Author(s):  
Xin-Wei He ◽  
Yu-Guang Shen ◽  
Min Zhu ◽  
Xiao-Fei Hu ◽  
Zhou Zheng ◽  
...  
Keyword(s):  
Gene Polymorphisms ◽  
Serum Levels ◽  
Large Artery

scholarly journals Galectin-3 Reflects Mitral Annular Plane Systolic Excursion Being Assessed by Cardiovascular Magnetic Resonance Imaging

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Seung-Hyun Kim ◽  
Michael Behnes ◽  
Michele Natale ◽  
Julia Hoffmann ◽  
Nadine Reckord ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Clinical Care ◽  
Area Under The Curve ◽  
Right Ventricular Dysfunction ◽  
Serum Levels ◽  
Resonance Imaging ◽  
Logistic Regression Models ◽  
Galectin 3 ◽  
I 11

Background. This study investigates whether serum levels of galectin-3 may reflect impaired mitral annular plane systolic excursion (MAPSE) in patients undergoing cardiac magnetic resonance imaging (cMRI).Methods. Patients undergoing cMRI during routine clinical care were included prospectively within an all-comers design. Blood samples for biomarker measurements were collected within 24 hours following cMRI. Statistical analyses were performed in all patients and in three subgroups according to MAPSE (MAPSE I: ≥11 mm, MAPSE II: ≥8 mm–<11 mm, and MAPSE III: <8 mm). Patients with right ventricular dysfunction (<50%) were excluded.Results. 84 patients were included in the study. Median LVEF was 59% (IQR 51–64%). Galectin-3 correlated significantly with NT-proBNP (r=0.42,p=0.0001). Galectin-3 increased significantly according to the different stages of impaired MAPSE (p=0.006) and was able to discriminate both patients with impaired MAPSE <11 mm (area under the curve (AUC) = 0.645,p=0.024) and <8 mm (AUC = 0.733,p=0.003). Combining galectin-3 with NT-proBNP improved discrimination of MAPSE <8 mm (AUC 0.803,p=0.0001). In multivariable logistic regression models galectin-3 was still associated with impaired MAPSE (MAPSE < 11 mm: odds ratio (OR) = 3.53,p=0.018; MAPSE < 8 mm: OR = 3.18,p=0.06).Conclusions. Galectin-3 reflects MAPSE being assessed by cardiac MRI.

Serum levels of galectin-3 in idiopathic inflammatory myopathies: a potential biomarker of disease activity

Rheumatology ◽  
2020 ◽  
Vol 60 (1) ◽  
pp. 322-332
Author(s):  
Eri Watanabe ◽  
Kazunori Kato ◽  
Takahisa Gono ◽  
Emiko Chiba ◽  
Chihiro Terai ◽  
...  
Keyword(s):  
Disease Activity ◽  
Interstitial Pneumonia ◽  
Activity Index ◽  
Biological Activities ◽  
Inflammatory Cells ◽  
Serum Levels ◽  
Idiopathic Inflammatory Myopathies ◽  
Inflammatory Myopathies ◽  
Potential Biomarker ◽  
Galectin 3

Abstract Objectives Galectin-3 is involved in various biological activities, including immune activations and fibrosis. Idiopathic inflammatory myopathies (IIMs) are autoimmune diseases of unknown aetiology, often complicated by interstitial lung disease (ILD). The aim of this study was to evaluate the expression of galectin-3 in sera and tissues of patients with IIM and assess the associations of galectin-3 with patient characteristics and disease activity. Results Serum galectin-3 levels were significantly higher in IIM patients than in healthy controls. The serum galectin-3 levels positively correlated with serum levels of inflammatory markers and proinflammatory cytokines/chemokines and the Myositis Intention-to-Treat Activity Index. Stratification analysis revealed that patients with IIM-associated ILD (IIM-ILD) had significantly higher levels of serum galectin-3 than those without IIM-ILD. In addition, patients with acute/subacute interstitial pneumonia had significantly higher levels of serum galectin-3 than those with chronic interstitial pneumonia. Furthermore, serum galectin-3 levels in IIM-ILD patients correlated with the radiological assessments of parenchymal lung involvement and treatment response. Immunohistochemical analysis revealed that galectin-3 was expressed in inflammatory cells of myositis and dermatitis sections, whereas in ILD sections, galectin-3 was expressed in interstitial fibrosis and inflammatory cells. Conclusion Galectin-3 may be involved in the pathogenesis of inflammatory and fibrotic conditions in IIM and can serve as a potential biomarker of disease activity, especially in patients with IIM-ILD.

scholarly journals Tsc2 disruption in mesenchymal progenitors results in tumors with vascular anomalies overexpressing Lgals3

eLife ◽  
2017 ◽  
Vol 6 ◽  
Author(s):  
Peter J Klover ◽  
Rajesh L Thangapazham ◽  
Jiro Kato ◽  
Ji-an Wang ◽  
Stasia A Anderson ◽  
...  
Keyword(s):  
Lung Function ◽  
Tuberous Sclerosis Complex ◽  
Serum Levels ◽  
Limb Bud ◽  
Mesenchymal Progenitors ◽  
Expression Signature ◽  
Mtorc1 Signaling ◽  
Impaired Lung Function ◽  
Galectin 3

Increased mTORC1 signaling from TSC1/TSC2 inactivation is found in cancer and causes tuberous sclerosis complex (TSC). The role of mesenchymal-derived cells in TSC tumorigenesis was investigated through disruption of Tsc2 in craniofacial and limb bud mesenchymal progenitors. Tsc2cKOPrrx1-cre mice had shortened lifespans and extensive hamartomas containing abnormal tortuous, dilated vessels prominent in the forelimbs. Abnormalities were blocked by the mTORC1 inhibitor sirolimus. A Tsc2/mTORC1 expression signature identified in Tsc2-deficient fibroblasts was also increased in bladder cancers with TSC1/TSC2 mutations in the TCGA database. Signature component Lgals3 encoding galectin-3 was increased in Tsc2-deficient cells and serum of Tsc2cKOPrrx1-cre mice. Galectin-3 was increased in TSC-related skin tumors, angiomyolipomas, and lymphangioleiomyomatosis with serum levels in patients with lymphangioleiomyomatosis correlating with impaired lung function and angiomyolipoma presence. Our results demonstrate Tsc2-deficient mesenchymal progenitors cause aberrant morphogenic signals, and identify an expression signature including Lgals3 relevant for human disease of TSC1/TSC2 inactivation and mTORC1 hyperactivity.

scholarly journals RETRACTED ARTICLE: Analysis of serum levels and tissue expression of galectin-1 and galectin-3 as noninvasive biomarkers in osteosarcoma patients

Tumor Biology ◽  
2015 ◽  
Vol 37 (12) ◽  
pp. 16389-16389 ◽  
Author(s):  
Ali Akbar Esmailiejah ◽  
Afshin Taheriazam ◽  
Mohammad Reza Golbakhsh ◽  
Mohammad Jamshidi ◽  
Mohammadreza Shakeri ◽  
...  
Keyword(s):  
Serum Levels ◽  
Tissue Expression ◽  
Article Analysis ◽  
Galectin 3 ◽  
Retracted Article ◽  
Noninvasive Biomarkers
Sign in / Sign up

Export Citation Format

Share Document